{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:42:35Z","timestamp":1792755755096,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10620-025-09139-z","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T03:38:39Z","timestamp":1750909119000},"page":"3937-3952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Selective Internal Radiation Therapy Combined with Immune Checkpoint Inhibitors in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Single-Arm Meta-Analysis"],"prefix":"10.1007","volume":"70","author":[{"given":"Miriana","family":"Mariussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Gallo Ruelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Costa de Oliveira Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Furtado Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Juliano Silva Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Guedes Moreira Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno","family":"Boueri Affonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Leonardo","family":"Galastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Luiz","family":"Serrano Uson Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Yuri Itaya Yamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Gobbo Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"9139_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ijc.32723","volume":"147","author":"JL Petrick","year":"2020","unstructured":"Petrick JL, Florio AA, Znaor A et al. International trends in hepatocellular carcinoma incidence, 1978\u20132012. Int. J. Cancer 2020;147:317\u2013330. https:\/\/doi.org\/10.1002\/ijc.32723.","journal-title":"Int. J. Cancer"},{"key":"9139_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 2018;68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA. Cancer J. Clin."},{"key":"9139_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatol. Baltim. Md 2018;68:723\u2013750. https:\/\/doi.org\/10.1002\/hep.29913.","journal-title":"Hepatol. Baltim. Md"},{"key":"9139_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 2022;76:681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J. Hepatol."},{"key":"9139_CR5","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1111\/j.1872-034X.2007.00186.x","volume":"37","author":"B Daniele","year":"2007","unstructured":"Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatol. Res. 2007;37:S206\u2013S209. https:\/\/doi.org\/10.1111\/j.1872-034X.2007.00186.x.","journal-title":"Hepatol. Res."},{"key":"9139_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s005350300038","volume":"38","author":"M Kudo","year":"2003","unstructured":"Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J. Gastroenterol. 2003;38:207\u2013215. https:\/\/doi.org\/10.1007\/s005350300038.","journal-title":"J. Gastroenterol."},{"key":"9139_CR7","doi-asserted-by":"publisher","unstructured":"Vogel A, Cervantes A, Chau I et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020, Ann. Oncol., vol. 29, pp. iv238\u2013iv255, 2018, https:\/\/doi.org\/10.1093\/annonc\/mdy308.","DOI":"10.1093\/annonc\/mdy308"},{"key":"9139_CR8","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1002\/lt.20036","volume":"10","author":"BI Carr","year":"2004","unstructured":"Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc. 2004;10:S107\u2013S110. https:\/\/doi.org\/10.1002\/lt.20036.","journal-title":"Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc."},{"key":"9139_CR9","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1097\/01.RVI.0000184594.01661.81","volume":"16","author":"R Salem","year":"2005","unstructured":"Salem R, Lewandowski RJ, Atassi B et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J. Vasc. Interv. Radiol. JVIR 2005;16:1627\u20131639. https:\/\/doi.org\/10.1097\/01.RVI.0000184594.01661.81.","journal-title":"J. Vasc. Interv. Radiol. JVIR"},{"key":"9139_CR10","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","volume":"9","author":"RJ Lewandowski","year":"2009","unstructured":"Lewandowski RJ, Kulik LM, Riaz A et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 2009;9:1920\u20131928. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02695.x.","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"9139_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jvir.2010.10.029","volume":"22","author":"R Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Gates VL et al. Research reporting standards for radioembolization of hepatic malignancies. J. Vasc. Interv. Radiol. JVIR 2011;22:265\u2013278. https:\/\/doi.org\/10.1016\/j.jvir.2010.10.029.","journal-title":"J. Vasc. Interv. Radiol. JVIR"},{"key":"9139_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00270-013-0600-8","volume":"36","author":"AH Mahnken","year":"2013","unstructured":"Mahnken AH, Spreafico C, Maleux G, Helmberger T, Jakobs TF. Standards of practice in transarterial radioembolization. Cardiovasc. Intervent. Radiol. 2013;36:613\u2013622. https:\/\/doi.org\/10.1007\/s00270-013-0600-8.","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"9139_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Kulik L et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140:497-507.e2. https:\/\/doi.org\/10.1053\/j.gastro.2010.10.049.","journal-title":"Gastroenterology"},{"key":"9139_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jhep.2011.07.012","volume":"56","author":"B Sangro","year":"2012","unstructured":"Sangro B, I\u00f1arrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J. Hepatol. 2012;56:464\u2013473. https:\/\/doi.org\/10.1016\/j.jhep.2011.07.012.","journal-title":"J. Hepatol."},{"key":"9139_CR15","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.2967\/jnumed.117.199752","volume":"59","author":"N Abouchaleh","year":"2018","unstructured":"Abouchaleh N, Gabr A, Ali R et al. 90Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2018;59:1042\u20131048. https:\/\/doi.org\/10.2967\/jnumed.117.199752.","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"9139_CR16","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 2020;382:1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N. Engl. J. Med."},{"key":"9139_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","volume":"40","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Chan SLam, Kudo M et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J. Clin. Oncol. 2022;40:379\u2013379. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.379.","journal-title":"J. Clin. Oncol."},{"key":"9139_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12885-020-6613-1","volume":"20","author":"L Craciun","year":"2020","unstructured":"Craciun L, de Wind R, Demetter P et al. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. BMC Cancer 2020;20:135. https:\/\/doi.org\/10.1186\/s12885-020-6613-1.","journal-title":"BMC Cancer"},{"key":"9139_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","volume":"68","author":"V Chew","year":"2019","unstructured":"Chew V, Lee YH, Pan L et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 2019;68:335\u2013346. https:\/\/doi.org\/10.1136\/gutjnl-2017-315485.","journal-title":"Gut"},{"key":"9139_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1089\/cbr.2022.0071","volume":"38","author":"K Ramdhani","year":"2023","unstructured":"Ramdhani K, Smits MLJ, Lam MGEH, Braat AJAT. Combining Selective Internal Radiation Therapy with Immunotherapy in Treating Hepatocellular Carcinoma and Hepatic Colorectal Metastases: A Systematic Review. Cancer Biother. Radiopharm. 2023;38:216\u2013224. https:\/\/doi.org\/10.1089\/cbr.2022.0071.","journal-title":"Cancer Biother. Radiopharm."},{"key":"9139_CR21","unstructured":"Corporation for Digital Scholarship, Zotero (Version 7.0.3). (2023). Accessed: Oct. 08, 2024. [Online]. Available: https:\/\/www.zotero.org\/"},{"key":"9139_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"9139_CR23","doi-asserted-by":"crossref","unstructured":"Bossuyt PM, Deeks JJ, Leeflang, MM, Takwoingi Y, Flemyng E. Preface, \u201cCochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0 (updated July 2023).\u201d [Online]. Available: Cochrane, 2023. Available from https:\/\/training.cochrane.org\/handbook-diagnostic-test-accuracy\/current","DOI":"10.1002\/14651858.ED000163"},{"key":"9139_CR24","first-page":"1","volume":"1","author":"CG Child","year":"1964","unstructured":"Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl. Clin. Surg. 1964;1:1\u201385.","journal-title":"Major Probl. Clin. Surg."},{"key":"9139_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 2010;30:52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132.","journal-title":"Semin. Liver Dis."},{"key":"9139_CR26","doi-asserted-by":"publisher","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. \u201cNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),\u201d Eur. J. Cancer Oxf. Engl. 1990, vol. 45, pp. 228\u2013247, 2009, https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"9139_CR27","unstructured":"National Cancer Institute (NCI), \u201cCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0,\u201d US Dep. Health Hum. Serv. Natl. Inst. Health Natl. Cancer Inst., 2017, Accessed: Sep. 20, 2024. [Online]. Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"9139_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"9139_CR29","unstructured":"G. Schwarzer, meta: General Package for Meta-Analysis. (Jan. 12, 2024). Accessed: Sep. 20, 2024. [Online]. Available: https:\/\/cran.r-project.org\/web\/packages\/meta\/index.html"},{"key":"9139_CR30","unstructured":"R Core Team, A Language and Environment for Statistical Computing. (2023). R Foundation for Statistical Computing, Vienna, Austria. Accessed: Jun. 13, 2024. [Online]. Available: https:\/\/www.R-project.org\/"},{"key":"9139_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1080\/00031305.1978.10479283","volume":"32","author":"JJ Miller","year":"1978","unstructured":"Miller JJ. The Inverse of the Freeman \u2013 Tukey Double Arcsine Transformation. Am. Stat. 1978;32:138\u2013138. https:\/\/doi.org\/10.1080\/00031305.1978.10479283.","journal-title":"Am. Stat."},{"key":"9139_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986;7:177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control. Clin. Trials"},{"key":"9139_CR33","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002;21:1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat. Med."},{"key":"9139_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2307\/3001666","volume":"10","author":"WG Cochran","year":"1954","unstructured":"Cochran WG. The Combination of Estimates from Different Experiments. Biometrics 1954;10:101. https:\/\/doi.org\/10.2307\/3001666.","journal-title":"Biometrics"},{"key":"9139_CR35","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/sim.1221","volume":"21","author":"B Baujat","year":"2002","unstructured":"Baujat B, Mah\u00e9 C, Pignon J-P, Hill C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat. Med. 2002;21:2641\u20132652. https:\/\/doi.org\/10.1002\/sim.1221.","journal-title":"Stat. Med."},{"key":"9139_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005457","author":"M de la Torre-Al\u00e1ez","year":"2022","unstructured":"de la Torre-Al\u00e1ez M, Matilla A, Varela M et al. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. J. Immunother. Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005457.","journal-title":"J. Immunother. Cancer"},{"key":"9139_CR37","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-23-0581","volume":"29","author":"YB Lee","year":"2023","unstructured":"Lee YB, Nam JY, Cho EJ et al. A Phase I\/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2023;29:3650\u20133658. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0581.","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"9139_CR38","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.jvir.2020.07.009","volume":"31","author":"B Marinelli","year":"2020","unstructured":"Marinelli B, Cedillo M, Pasik SD et al. Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients. J. Vasc. Interv. Radiol. JVIR 2020;31:1729-1738.e1. https:\/\/doi.org\/10.1016\/j.jvir.2020.07.009.","journal-title":"J. Vasc. Interv. Radiol. JVIR"},{"key":"9139_CR39","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","volume":"6","author":"D Tai","year":"2021","unstructured":"Tai D, Loke K, Gogna A, Kaya NA et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209\u2013678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol. Hepatol. 2021;6:1025\u20131035. https:\/\/doi.org\/10.1016\/S2468-1253(21)00305-8.","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"9139_CR40","doi-asserted-by":"publisher","first-page":"10100","DOI":"10.3390\/curroncol30120734","volume":"30","author":"A Villalobos","year":"2023","unstructured":"Villalobos A, Dabbous HH, Little O et al. Safety and Efficacy of Concurrent Atezolizumab\/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma. Curr. Oncol. Tor. Ont 2023;30:10100\u201310110. https:\/\/doi.org\/10.3390\/curroncol30120734.","journal-title":"Curr. Oncol. Tor. Ont"},{"key":"9139_CR41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/oncolo\/oyad331","volume":"29","author":"S Yu","year":"2024","unstructured":"Yu S, Yu M, Keane B et al. A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma. The oncologist 2024;29:270-e413. https:\/\/doi.org\/10.1093\/oncolo\/oyad331.","journal-title":"The oncologist"},{"key":"9139_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","volume":"31","author":"C Zhan","year":"2020","unstructured":"Zhan C, Ruohoniemi D, Shanbhogue KP et al. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma. J. Vasc. Interv. Radiol. JVIR 2020;31:25\u201334. https:\/\/doi.org\/10.1016\/j.jvir.2019.05.023.","journal-title":"J. Vasc. Interv. Radiol. JVIR"},{"key":"9139_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.764189","volume":"11","author":"M Zhou","year":"2021","unstructured":"Zhou M, Zhang C, Nie J et al. Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria. Front. Oncol. 2021;11:764189. https:\/\/doi.org\/10.3389\/fonc.2021.764189.","journal-title":"Front. Oncol."},{"key":"9139_CR44","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00270-020-02467-9","volume":"43","author":"F Estrade","year":"2020","unstructured":"Estrade F, Lescure C, Muzellec L et al. Lymphocytes and Neutrophil-to-Lymphocyte Ratio Variations After Selective Internal Radiation Treatment for HCC: A Retrospective Cohort Study. Cardiovasc. Intervent. Radiol. 2020;43:1175\u20131181. https:\/\/doi.org\/10.1007\/s00270-020-02467-9.","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"9139_CR45","doi-asserted-by":"publisher","first-page":"41242","DOI":"10.18632\/oncotarget.17168","volume":"8","author":"K-J Kim","year":"2017","unstructured":"Kim K-J, Kim J-H, Lee SJ, Lee E-J, Shin E-C, Seong J. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget 2017;8:41242\u201341255. https:\/\/doi.org\/10.18632\/oncotarget.17168.","journal-title":"Oncotarget"},{"key":"9139_CR46","doi-asserted-by":"publisher","first-page":"13012","DOI":"10.1073\/pnas.95.22.13012","volume":"95","author":"N Li","year":"1998","unstructured":"Li N, Karin M. Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc. Natl. Acad. Sci. U. S. A. 1998;95:13012\u201313017. https:\/\/doi.org\/10.1073\/pnas.95.22.13012.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"9139_CR47","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity 2014;41:843\u2013852. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019.","journal-title":"Immunity"},{"key":"9139_CR48","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Nirschl CJ, Kochel CM et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol. Res. 2015;3:345\u2013355. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0196.","journal-title":"Cancer Immunol. Res."},{"key":"9139_CR49","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet Lond. Engl. 2017;389:2492\u20132502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2.","journal-title":"Lancet Lond. Engl."},{"key":"9139_CR50","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940\u2013952. https:\/\/doi.org\/10.1016\/S1470-2045(18)30351-6.","journal-title":"Lancet Oncol."},{"key":"9139_CR51","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624\u20131636. https:\/\/doi.org\/10.1016\/S1470-2045(17)30683-6.","journal-title":"Lancet Oncol."},{"key":"9139_CR52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jvir.2021.03.535","volume":"32","author":"S Frantz","year":"2021","unstructured":"Frantz S, Matsuoka L, Vaheesan K et al. Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry. J. Vasc. Interv. Radiol. 2021;32:845\u2013852. https:\/\/doi.org\/10.1016\/j.jvir.2021.03.535.","journal-title":"J. Vasc. Interv. Radiol."},{"key":"9139_CR53","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.jhepr.2022.100633","volume":"5","author":"F Kolligs","year":"2023","unstructured":"Kolligs F, Arnold D, Golfieri R et al. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study. JHEP Rep. Innov. Hepatol. 2023;5:100633. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100633.","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"9139_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, Cheng AL et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23:77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00604-5.","journal-title":"Lancet Oncol."},{"key":"9139_CR55","doi-asserted-by":"publisher","first-page":"LBA4008","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008","volume":"42","author":"T Yau","year":"2024","unstructured":"Yau T, Decaens T, Sangro B, Qin S, da Fonseca LG et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. J. Clin. Oncol. 2024;42:LBA4008. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA4008.","journal-title":"J. Clin. Oncol."},{"key":"9139_CR56","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018;15:599\u2013616. https:\/\/doi.org\/10.1038\/s41571-018-0073-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"9139_CR57","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","volume":"153","author":"D Sia","year":"2017","unstructured":"Sia D, Jiao Y, Martinez-Quetglas I et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology 2017;153:812\u2013826. https:\/\/doi.org\/10.1053\/j.gastro.2017.06.007.","journal-title":"Gastroenterology"},{"key":"9139_CR58","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000515305","volume":"10","author":"CL Hsu","year":"2021","unstructured":"Hsu CL, Ou DL, Bai LY et al. Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Liver Cancer 2021;10:346\u2013359. https:\/\/doi.org\/10.1159\/000515305.","journal-title":"Liver Cancer"},{"key":"9139_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol. Hepatol. 2021;6:17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9.","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"9139_CR60","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","volume":"40","author":"MZ Wojtukiewicz","year":"2021","unstructured":"Wojtukiewicz MZ, Rek MM, Karpowicz K et al. Inhibitors of immune checkpoints\u2014PD-1, PD-L1, CTLA-4\u2014new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021;40:949\u2013982. https:\/\/doi.org\/10.1007\/s10555-021-09976-0.","journal-title":"Cancer Metastasis Rev."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09139-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09139-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09139-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T17:02:57Z","timestamp":1763485377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09139-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["9139"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09139-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5379612\/v1","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"2 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}